Compton Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Compton Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-26,400	Closed	-$18K	–	165
2020 Q4	$18K	Sell	26,400 -500	-2%	-$1.06K	0.01%	152
2020 Q3	$61K	Sell	26,900 -350	-1%	-$1K	0.02%	133
2020 Q2	$98K	Hold	27,250	–	–	0.04%	128
2020 Q1	$104K	Sell	27,250 -120	-0.4%	-$395	0.05%	123
2019 Q4	$82K	Buy	+27,370	New	+$71.2K	0.03%	138

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Compton Capital Management's BMY.RT Position: Q1 2021 in Review

Compton Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 26,400 shares — an estimated $18K sold.

Compton Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $104K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Compton Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Compton Capital Management sold 26,400 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $18K.
Compton Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Compton Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $104K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Compton Capital Management's 13F filing for Q1 2021, filed 4 May 2021.